13F Holdings
中文EN

ASBP Aspire-Lakewood Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1847345 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY41.6%
TTM EPS YoY201.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-25.0%
Operating margin-7,494.8%
Net margin-11,314.1%
FCF margin—
EBITDA margin—

Returns

ROE-1,032.1%
ROA-152.1%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.2%
Debt / equity0.00x
Current ratio7.99x
Interest coverage-0.79x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-53.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-312024Q32024-09-30
Income statement
Revenue$63,104$28,353$4,261$1,941————
Cost of revenue$50,818$22,603$5,261$1,057————
Gross profit-$30,086$5,750-$1,000$884————
R&D expense$233,482$296,723$100,035$207,899$352,887$263,093$116,356$7,000
SG&A expense$970,211$1.02M$1.66M$512,993$395,692$15.07M$529,616$191,578
Operating income-$2.68M-$1.65M-$1.85M-$1.15M-$799,890-$15.56M-$667,722-$215,256
Interest expense$0$1.60M$6.23M$1.48M$527,893$289,931——
Pretax income-$1.27M-$3.22M——-$1.98M-$15.94M——
Income tax——————$0$1,013
Net income-$1.27M-$3.22M-$4.71M-$1.85M-$1.98M-$15.94M-$765,710-$216,269
EPS (basic)-1.22-20.57—-0.04-48.19-504.88—-0.01
EPS (diluted)-1.22-20.57—-0.04-48.19-504.88—-0.01
Weighted avg. shares (diluted)1.04M156,685—49.53M41,11131,575—27.60M
Balance sheet
Cash & equivalents$12.17M$5.86M$1.00M$1.95M$206,233$1.35M$3,633$16,541
Inventory$288,450$369,974$253,160$35,437————
Current assets$13.47M$7.12M$1.31M$2.40M$989,422$1.97M$147,989$61,809
Total assets$13.54M$7.12M$1.31M$2.40M$989,422$1.97M$147,989$6.66M
Current liabilities$1.69M$3.15M$7.59M$13.86M$10.56M$9.87M$1.69M$6.57M
Total liabilities$1.78M$3.25M$7.69M$13.87M$10.61M$9.92M$1.69M$6.57M
Shareholders' equity$11.76M$3.87M-$6.38M-$11.47M-$9.62M-$7.95M-$1.54M-$774,378
Shares outstanding1.30M167,470117,78049.53M49.53M48.90M690,044—
Cash flow statement
Operating cash flow-$2.12M-$3.04M-$927,841-$1.10M-$1.14M-$1.75M$479,569-$495,540
Investing cash flow——————$0$0
Financing cash flow$8.43M$7.89M-$16,526$2.85M$0$3.09M-$492,477$492,477
Stock-based compensation$157,500$13,406$0$0$0$14.13M$0$0
Share buybacks——————$0$0

Free plan shows the latest 8 periods; Pro shows all 20 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.